Auckland-based biotech firm Pictor says a new partnership with Scienion, a subsidiary of Stockholm listed Bico, to commercialise a high-throughput Covid-19 antibody testing system will take its business to new revenue heights.
The companies will incorporate Scienion’s CL2 sciREADER system into
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
